Carbonic anhydrase IX as a target for designing novel anticancer drugs

Current Medicinal Chemistry

Volumn 19, Issue 6, 2012, Pages 821-830

  Monti, S M ^a   Supuran, C T ^b   De Simone, G ^a  

^a CNR   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Anti tumor drugs; Carbonic anhydrase IX; Inhibitors; Monoclonal antibody; Structure based drug design

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE IX; COUMARIN; IMATINIB; MONOCLONAL ANTIBODY; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SULFONAMIDE;

BINDING AFFINITY; CATALYSIS; DRUG DESIGN; ENZYME STRUCTURE; HUMAN; HYPOXIA; NONHUMAN; REVIEW;

ANIMALS; ANOXIA; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASES; DRUG DESIGN; HUMANS; NEOPLASMS;

EID: 84857555235     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712799034851     Document Type: Review

References (113)

1. Supuran, C. T. Carbonic anhydrases: Novel therapeutic applications for inhibitors and activators. Nat. Rev. Drug Discov., 2008, 7, 168-181. (Pubitemid 351194064)
2. Krishnamurthy, V. M.; Kaufman, G. K.; Urbach, A. R.; Gitlin, I.; Gudiksen, K. L.; Weibel, D. B.; Whitesides, G. M. Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem. Rev., 2008, 108, 946-1051. (Pubitemid 351577855)
3. Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications, Supuran, C. T.; Winum, J.-Y. Eds.; Wiley: Hoboken, New Jersey, 2009; Part II.
4. Carbonic Anhydrase: Its Inhibitors and Activators, Supuran, C. T.; Scozzafava, A.; Conway, J. Eds.; CRC Press: Boca Raton, FL, 2004.
5. Maren, T. H. Carbonic anhydrase: Chemistry, physiology, and inhibition. Physiol. Rev., 1967, 47, 595-781.
6. Pastorek, J.; Pastoreková, S.; Callebaut, I.; Mornon, J.P.; Zelník, V.; Opavsk, R.; Zat'ovicová, M.; Liao, S.; Portetelle, D.; Stanbridge, E.J.; Závada, J.; Burny, A.; Kettmann, R. Cloning and characterization of MN, a human tumor-Associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene, 1994, 9, 2877-2888.
7. Opavsk, R.; Pastoreková, S.; Zelnik, V.; Gibadulinová, A.; Stanbridge, E.J.; Závada, J.; Kettmann, R.; Pastorek, J. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: Structure and exon to protein domain relationships. Genomics, 1996, 33, 480-487. (Pubitemid 26159864)
8. Supuran, C.T.; Di Fiore, A.; Alterio, V.; Monti, S.M.; De Simone, G. Recent advances in structural studies of the carbonic anhydrase family: The crystal structure of human CA IX and CA XIII. Curr. Pharm. Des., 2010, 16, 3246-3254.
9. De Simone, G.; Supuran, C.T. Carbonic anhydrase IX: Biochemical and crystallographic characterization of a novel antitumor target. Biochim. Biophys. Acta, 2010, 1804, 404-409.
10. Guler, O.O.; De Simone, G.; Supuran, C.T. Drug design studies of the novel antitumor targets carbonic anhydrase IX and XII. Curr. Med. Chem., 2010, 17, 1516-1526.
11. Zatovicova, M.; Jelenska, L.; Hulikova, A.; Csaderova, L.; Ditte, Z.; Ditte, P.; Goliasova, T.; Pastorek, J.; Pastorekova, S. Carbonic anhydrase IX as an anticancer therapy target: Preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. Curr. Pharm. Des., 2010, 16, 3255-3263.
12. Pastorekova, S.; Zatovicova, M.; Pastorek, J. Cancer-Associated carbonic anhydrases and their inhibition. Curr. Pharm. Des., 2008, 14, 685-698. (Pubitemid 351736449)
13. Pastoreková, S.; Závadová, Z.; Kostál, M.; Babusíková, O.; Závada, J. A novel quasi-viral agent, MaTu, is a two-component system. Virology, 1992, 187, 620-626.
14. Pastoreková, S.; Parkkila, S.; Parkkila, A.K.; Opavsk, R.; Zelník, V.; Saarnio, J.; Pastorek, J. Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology, 1997, 112, 398-408. (Pubitemid 27078826)
15. Saarnio, J.; Parkkila, S.; Parkkila, A.K.; Waheed, A.; Casey, M.C., Zhou, X.Y., Pastoreková, S., Pastorek, J., Karttunen, T., Haukipuro, K., Kairaluoma, M.I., Sly, W.S. Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. J. Histochem. Cytochem., 1998, 46, 497-504.
16. Stillebroer, A.B.; Mulders, P.F.; Boerman, O.C.; Oyen, W.J.; Oosterwijk, E. Carbonic anhydrase IX in renal cell carcinoma: Implications for prognosis, diagnosis, and therapy. Eur. Urol., 2010, 58, 75-83.
17. Pastoreková, S., Pastorek, J. In: Carbonic Anhydrase: Its Inhibitors and Activators; Supuran, C.T.; Scozzafava, A.; Conway, J. Eds; -CRC Press. Boca Raton, FL, 2004; pp 255-281.
18. Barnea, G.; Grumet, M.; Milev, P.; Silvennoinen, O.; Levy, J.B.; Sap, J.; Schlessinger, J. Receptor tyrosine phosphatase beta is expressed in the form of proteoglycan and binds to the extracellular matrix protein tenascin. J. Biol. Chem., 1994, 269, 14349-14352. (Pubitemid 24193978)
19. Peles, E.; Nativ, M.; Campbell, P.L.; Sakurai, T.; Martinez, R.; Lev, S.; Clary, D.O.; Schilling, J.; Barnea, G.; Plowman, G.D.; Grumet, M.; Schlessinger, J. The carbonic anhydrase domain of receptor tyrosine phosphatase beta is a functional ligand for the axonal cell recognition molecule contactin. Cell, 1995, 82, 251-260.
20. Parent, A.S.; Mungenast, A.E.; Lomniczi, A.; Sandau, U.S.; Peles, E.; Bosch, M.A.; Rønnekleiv, O.K.; Ojeda, S.R. A contactin-receptor-like protein tyrosine phosphatase beta complex mediates adhesive communication between astroglial cells and gonadotrophin-releasing hormone neurones. J. Neuroendocrinol., 2007, 19, 847-859.
21. Hilvo, M.; Baranauskiene, L.; Salzano, A.M.; Scaloni, A.; Matulis, D.; Innocenti, A.; Scozzafava, A.; Monti, S.M.; Di Fiore, A.; De Simone, G.; Lindfors, M.; Jänis, J.; Valjakka, J.; Pastoreková, S.; Pastorek, J.; Kulomaa, M.S., Nordlund, H.R.; Supuran, C.T.; Parkkila. S. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J. Biol. Chem., 2008, 283, 27799-27809.
22. Funderburgh, J. L. Keratan sulfate: Structure, biosynthesis, and function. Glycobiology, 2000, 10, 951-958.
23. Dorai, T.; Sawczuk, I.S.; Pastorek, J.; Wiernik, P.H.; Dutcher, J.P. The role of carbonic anhydrase IX overexpression in kidney cancer. Eur. J. Cancer., 2005, 41, 2935-2947. (Pubitemid 41713134)
24. Wingo, T.; Tu, C.; Laipis, P.J.; Silverman, D.N. The catalytic properties of human carbonic anhydrase IX. Biochem. Biophys. Res. Commun., 2001, 288, 666-669. (Pubitemid 33030081)
25. 2 hydration at acidic pH values characteristic of solid tumors. Bioorg Med Chem Lett., 2009, 19, 5825-5828.
26. Alterio, V.; Hilvo, M.; Di Fiore, A.; Supuran, C.T.; Pan, P.; Parkkila, S.; Scaloni, A.; Pastorek, J.; Pastorekova, S.; Pedone, C.; Scozzafava, A.; Monti, S.M.; De Simone, G. Crystal structure of the catalytic domain of the tumorassociated human carbonic anhydrase IX. Proc. Natl. Acad. Sci. USA, 2009, 106, 16233-16238.
27. Maxwell, P.H.; Wiesener, M.S.; Chang, G.W.; Clifford, S.C.; Vaux, E.C.; Cockman, M.E.; Wykoff, C.C.; Pugh, C.W.; Maher, E.R.; Ratcliffe, P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 1999, 399, 271-275. (Pubitemid 29246458)
28. Huang, L.E.; Bunn, H.F. Hypoxia-inducible factor and its biomedical relevance J. Biol. Chem., 2003, 278, 19575-19578. (Pubitemid 36799137)
29. Coleman, M.L.; Ratcliffe, P.J. Oxygen sensing and hypoxia-induced responses. Essays Biochem., 2007, 43, 1-15.
30. Wykoff, C.C.; Beasley, N.J.; Watson, P.H.; Turner, K.J.; Pastorek, J.; Sibtain, A.; Wilson, G.D.; Turley, H.; Talks, K.L.; Maxwell, P.H.; Pugh, C.W.; Ratcliffe, P.J.; Harris, A.L. Hypoxia-inducible expression of tumorassociated carbonic anhydrases. Cancer Res., 2000, 60,7075-7083. (Pubitemid 32059187)
31. Pastorekova, S.; Barathova, M.; Kopacek, J.; Pastorek, J. In: Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications; Supuran, C. T.; Winum, J.-Y.; Eds.; Wiley: Hoboken, New Jersey, 2009; 193-222.
32. Stubbs, M.; McSheehy, P.M.; Griffiths, J.R.; Bashford, C.L. Causes and consequences of tumour acidity and implications for treatment. Mol. Med. Today, 2000, 6, 15-19. (Pubitemid 30010232)
33. Helmlinger, G.; Sckell, A.; Dellian, M.; Forbes, N.S.; Jain, R.K. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin. Cancer Res., 2002, 8, 1284-1291. (Pubitemid 35177386)
34. Fukumura, D.; Jain, R.K. Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize. J. Cell Biochem., 2007, 101, 937-949. (Pubitemid 47040874)
35. Swietach, P.; Hulikova, A.; Vaughan-Jones, R.D.; Harris, A.L. New insights into the physiological role of carbonic anhydrase IX in tumour pH regulation. Oncogene, 2010, 29, 6509-6521.
36. Martinez-Zaguilan, R.; Lynch, R.M.; Martinez, G.M.; Gillies, R.J. Vacuolartype H(+)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am. J. Physiol., 1993, 265, C1015-C1029.
37. Lee, A.H.; Tannock, I.F. Heterogeneity of intracellular pH and of mechanisms that regulate intracellular pH in populations of cultured cells. Cancer Res., 1998, 58, 1901-1908. (Pubitemid 28217465)
38. McLean, L.A.; Roscoe, J.; Jorgensen, N.K.; Gorin, F.A.; Cala, P.M. Malignant gliomas display altered pH regulation by NHE1 compared with nontransformed astrocytes. Am. J. Physiol. Cell Physiol., 2000, 278, C676-C688. (Pubitemid 30211300)
39. Boron, W.F. Regulation of intracellular pH. Adv. Physiol. Educ., 2004, 28, 160-179.
40. Chiche, J.; Brahimi-Horn, M.C.; Pouysségur, J. Tumour hypoxia induces a metabolic shift causing acidosis: A common feature in cancer. J. Cell. Mol. Med. 2010, 14, 771-794.
41. Brahimi-Horn, M.C.; Pouysségur, J. Hypoxia in cancer cell metabolism and pH regulation. Essays Biochem., 2007, 43, 165-178.
42. Swietach, P.; Vaughan-Jones, R.D.; Harris, A.L. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev., 2007, 26, 299-310. (Pubitemid 47101667)
43. Morgan, P.E.; Pastoreková, S.; Stuart-Tilley, A.K.; Alper, S.L.; Casey, J.R. Interactions of transmembrane carbonic anhydrase, CAIX, with bicarbonate transporters. Am. J. Physiol. Cell Physiol., 2007, 293, C738-C748. (Pubitemid 47235179)
44. Svastová, E.; Hulíková, A.; Rafajová, M.; Zat'ovicová, M.; Gibadulinová, A.; Casini, A.; Cecchi, A.; Scozzafava, A.; Supuran, C,T.; Pastorek, J.; Pastoreková, S. Hypoxia activates the capacity of tumor-Associated carbonic anhydrase IX to acidify extracellular pH. FEBS Lett., 2004, 577, 439-445. (Pubitemid 39535327)
45. Swietach, P.; Wigfield, S.; Supuran, C.T.; Harris, A.L.; Vaughan-Jones, R.D. Tumor-Associated carbonic anhydrase 9 spatially coordinates intracellular pH in three-dimensional multicellular growths. BJU Int., 2008, 101, Suppl 4:22-24.
46. Swietach, P.; Patiar, S.; Supuran, C.T.; Harris A.L.; Vaughan-Jones, R.D. The role of carbonic anhydrase 9 in regulating extracellular and intracellular pH in three-dimensional tumor cell growths. J. Biol. Chem. 2009, 284, 20299-20310.
47. Casey, J.R. Why bicarbonate? Biochem. Cell Biol., 2006, 84, 930-939. (Pubitemid 46450693)
48. Cecchi, A.; Hulikova, A.; Pastorek, J.; Pastoreková, S.; Scozzafava, A.; Winum, J.Y.; Montero, J.L.; Supuran, C.T. Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-Associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. J. Med. Chem., 2005, 48, 4834-4841. (Pubitemid 41033126)
49. Dubois, L.; Douma, K.; Supuran, C.T.; Chiu, R.K.; van Zandvoort, M.A.; Pastoreková, S.; Scozzafava, A.; Wouters, B.G.; Lambin, P. Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. Radiother. Oncol., 2007, 83, 367-373. (Pubitemid 46915545)
50. Svastová, E.; Zilka, N.; Zat'ovicová, M.; Gibadulinová, A.; Ciampor, F.; Pastorek, J.; Pastoreková, S. Carbonic anhydrase IX reduces E-cadherinmediated adhesion of MDCK cells via interaction with beta-catenin. Exp. Cell Res., 2003, 290, 332-345. (Pubitemid 37272176)
51. Zavadova, Z.; Zavada, J. Carbonic anhydrase IX (CA IX) mediates tumor cell interactions with microenvironment. Oncol. Rep., 2005, 13, 977-982.
52. Závada, J.; Závadová, Z.; Pastorek, J.; Biesová, Z.; Jezek, J.; Velek, J. Human tumour-Associated cell adhesion protein MN/CA IX: Identification of M75 epitope and of the region mediating cell adhesion. Br. J. Cancer., 2000, 82, 1808-1813. (Pubitemid 30307393)
53. Hulikova, A.; Zatovicova, M.; Svastova, E.; Ditte, P.; Brasseur, R.; Kettmann, R.; Supuran, C.T.; Kopacek, J.; Pastorek, J.; Pastorekova, S. Intact intracellular tail is critical for proper functioning of the tumorassociated, hypoxia-regulated carbonic anhydrase IX. FEBS Lett., 2009, 583, 3563-3568.
54. Kannan, K. K.; Ramanadham, M.; Jones, T. A. Structure, refinement, and function of carbonic anhydrase isozymes: Refinement of human carbonic anhydrase I. Ann. N.Y. Acad. Sci., 1984, 429, 49-60. (Pubitemid 14085829)
55. Eriksson, A. E.; Kylsten, P. M.; Jones, T. A.; Liljas, A. Crystallographic studies of inhibitor binding sites in human carbonic anhydrase II: A pentacoordinated binding of the SCN-ion to the zinc at high pH. Proteins, 1988, 4, 283-293. (Pubitemid 19094187)
56. Eriksson, A. E.; Liljas, A. Refined structure of bovine carbonic anhydrase III at 2.0 A resolution. Proteins, 1993, 16, 29-42. (Pubitemid 23129870)
57. Boriack-Sjodin, P. A.; Heck, R. W.; Laipis, P. J.; Silverman, D. N.; Christianson, D. W. Structure determination of murine mitochondrial carbonic anhydrase V at 2.45-A resolution: Implications for catalytic proton transfer and inhibitor design. Proc. Natl. Acad. Sci. U.S.A., 1995, 92, 10949-10953.
58. Stams, T.; Nair, S. K.; Okuyama, T.; Waheed, A.; Sly, W. S.; Christianson, D. W. Crystal structure of the secretory form of membrane-Associated human carbonic anhydrase IV at 2.8-A resolution. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 13589-13594.
59. Whittington, D. A.; Waheed, A.; Ulmasov, B.; Shah, G. N.; Grubb, J. H.; Sly, W. S.; Christianson, D. W. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 9545-9550. (Pubitemid 32769340)
60. Whittington, D. A.; Grubb, J. H.; Waheed, A.; Shah, G. N.; Sly, W. S.; Christianson, D. W. Expression, assay, and structure of the extracellular domain of murine carbonic anhydrase XIV: Implications for selective inhibition of membrane-Associated isozymes. J. Biol. Chem., 2004, 279, 7223-7228. (Pubitemid 38248870)
61. Duda, D. M.; Tu, C.; Fisher, S. Z.; An, H.; Yoshioka, C.; Govindasamy, L.; Laipis, P. J.; Agbandje-McKenna, M.; Silverman, D. N.; McKenna, R. Human carbonic anhydrase III: Structural and kinetic study of catalysis and proton transfer. Biochemistry, 2005, 44, 10046-10053. (Pubitemid 41076800)
62. Di Fiore, A.; Monti, S. M.; Hilvo, M.; Parkkila, S.; Romano, V.; Scaloni, A.; Pedone, C.; Scozzafava, A.; Supuran, C. T.; De Simone, G. Crystal structure of human carbonic anhydrase XIII and its complex with the inhibitor acetazolamide. Proteins, 2009, 74, 164-175.
63. Di Fiore, A.; Truppo, E.; Supuran, C. T.; Alterio, V.; Dathan, N.; Bootorabi, F.; Parkkila, S.; Monti, S. M.; De Simone, G. Crystal structure of the C183S/C217S mutant of human CA VII in complex with acetazolamide. Bioorg. Med. Chem. Lett., 2010, 20, 5023-5026.
64. Alterio, V.; Di Fiore, A.; D'Ambrosio, K.; Supuran, C. T.; De Simone, G. In: Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications; Supuran, C. T., Winum, J.-Y., Eds.; Wiley: Hoboken, New Jersey, 2009; p 73-138.
65. Domsic, J. F.; Avvaru, B. S.; Kim, C. U.; Gruner, S. M.; Agbandje-McKenna, M.; Silverman, D. N.; McKenna, R. Entrapment of carbon dioxide in the active site of carbonic anhydrase II. J. Biol. Chem., 2008, 283, 30766-30771.
66. Merz, K. M. Jr. Carbon dioxide binding to human carbonic anhydrase II. J. Am. Chem. Soc., 1991, 113, 406-411.
67. Tu, C. K.; Silverman, D. N.; Forsman, C.; Jonsson, B. H.; Lindskog, S. Role of histidine 64 in the catalytic mechanism of human carbonic anhydrase II studied with a site-specific mutant. Biochemistry, 1989, 28, 7913-7918. (Pubitemid 19238127)
68. Silverman, D. N.; McKenna, R. Solvent-mediated proton transfer in catalysis by carbonic anhydrase. Acc. Chem. Res., 2007, 40, 669-675.
69. Roy, A.; Taraphder, S. Identification of proton-transfer pathways in human carbonic anhydrase II. J. Phys. Chem. Sect. B., 2007, 111, 10563-10576. (Pubitemid 47441861)
70. Fisher, S. Z.; Maupin, C. M.; Budayova-Spano, M.; Govindasamy, L.; Tu, C. K.; Agbandje-McKenna, M.; Silverman, D. N.; Voth, G. A.; McKenna, R. Atomic crystal and molecular dynamics simulation structures of human carbonic anhydrase II: Insights into the proton transfer mechanism. Biochemistry, 2007, 46, 2930-2937. (Pubitemid 46449117)
71. Chrastina, A.; Závada, J.; Parkkila, S.; Kaluz, S.; Kaluzová, M.; Rajcáni, J.; Pastorek, J.; Pastoreková, S. Biodistribution and pharmacokinetics of 125Ilabeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma. Int. J. Cancer., 2003, 105, 873-881. (Pubitemid 36706114)
72. Klatte, T.; Seligson, D.B.; Rao, J.Y.; Yu, H.; de Martino, M.; Kawaoka, K.; Wong, S.G.; Belldegrun, A.S.; Pantuck, A.J. Carbonic anhydrase IX in bladder cancer: A diagnostic, prognostic, and therapeutic molecular marker. Cancer, 2009, 115, 1448-1458.
73. Jensen, H.K.; Nordsmark, M.; Donskov, F.; Marcussen, N.; von der Maase, H. Immunohistochemical expression of carbonic anhydrase IX assessed over time and during treatment in renal cell carcinoma. BJU Int., 2008, 101, 41-44.
74. Oosterwijk, E.; Ruiter, D.J.; Hoedemaeker, P.J.; Pauwels, E.K.; Jonas, U.; Zwartendijk, J.; Warnaar, S.O. Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer, 1986, 38, 489-494. (Pubitemid 16006918)
75. Grabmaier, K.; Vissers, J.L.; De Weijert, M.C.; Oosterwijk-Wakka, J.C.; Van Bokhoven, A.; Brakenhoff, R.H.; Noessner, E.; Mulders, P.A.; Merkx, G.; Figdor, C.G.; Adema, G.J.; Oosterwijk, E. Molecular cloning and immunogenicity of renal cell carcinoma-Associated antigen G250. Int. J. Cancer, 2000, 85, 865-870. (Pubitemid 30131479)
76. Oosterwijk, E.; Bander, N.H.; Divgi, C.R.; Welt, S.; Wakka, J.C.; Finn, R.D.; Carswell, E.A.; Larson, S.M.; Warnaar, S.O.; Fleuren, G.J. Antibody localization in human renal cell carcinoma: A phase I study of monoclonal antibody G250. J. Clin. Oncol., 1993, 11, 738-750. (Pubitemid 23105683)
77. Oosterwijk, E. Carbonic anhydrase IX: Historical and future perspectives. BJU Int., 2008, 101, Suppl 4:2-7.
78. Divgi, C.R.; Bander, N.H.; Scott, A.M.; O'Donoghue, J.A.; Sgouros, G.; Welt, S.; Finn, R.D.; Morrissey, F.; Capitelli, P.; Williams, J.M.; Deland, D.; Nakhre, A.; Oosterwijk, E.; Gulec, S.; Graham, M.C.; Larson, S.M.; Old, L.J. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin. Cancer Res., 1998, 4, 2729-2739. (Pubitemid 28523499)
79. Steffens, M.G.; Boerman, O.C.; Oosterwijk-Wakka, J.C.; Oosterhof, G.O.; Witjes, J.A.; Koenders, E.B.; Oyen, W.J.; Buijs, W.C.; Debruyne, F.M.; Corstens, F.H.; Oosterwijk, E. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J. Clin. Oncol., 1997, 15, 1529-1537. (Pubitemid 27167389)
80. Steffens, M.G.; Boerman, O.C.; de Mulder, P.H.; Oyen, W.J.; Buijs, W.C.; Witjes, J.A.; van den Broek, W.J.; Oosterwijk-Wakka, J.C.; Debruyne, F.M.; Corstens, F.H.; Oosterwijk, E. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin. Cancer Res., 1999, 5, (10 Suppl):3268s-3274s. (Pubitemid 29493926)
81. Brouwers, A.H.; Mulders, P.F.; de Mulder, P.H.; van den Broek, W.J.; Buijs, W.C.; Mala, C.; Joosten, F.B.; Oosterwijk, E.; Boerman, O.C.; Corstens, F.H.; Oyen, W.J. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J. Clin. Oncol., 2005, 23, 6540-6548. (Pubitemid 46190246)
82. Pryma, D.A.; O'Donoghue, J.A.; Humm, J.L.; Jungbluth, A.A.; Old, L.J.; Larson, S.M.; Divgi, C.R. Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250. J. Nucl. Med., 2011, 52, 535-540.
83. Brouwers, A.H.; van Eerd, J.E.; Frielink, C.; Oosterwijk, E.; Oyen, W.J.; Corstens, F.H.; Boerman, O.C. Optimization of radioimmunotherapy of renal cell carcinoma: Labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J. Nucl. Med., 2004, 45, 327-337. (Pubitemid 47618658)
84. Siebels, M.; Rohrmann, K.; Oberneder, R.; Stahler, M.; Haseke, N.; Beck, J.; Hofmann, R.; Kindler, M.; Kloepfer, P.; Stief, C. A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-Alpha-2a in metastatic renal cell carcinoma patients. World J. Urol., 2011, 29, 121-126.
85. Reichert, J.M. Antibody-based therapeutics to watch in 2011. MAbs, 2011, 3, 76-99.
86. Hoeben, B.A.; Kaanders, J.H.; Franssen, G.M.; Troost, E.G.; Rijken, P.F.; Oosterwijk, E.; van Dongen, G.A.; Oyen, W.J.; Boerman, O.C.; Bussink, J. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors. J. Nucl. Med., 2010, 51, 1076-1083.
87. Chopra, A. [111In]-Labeled divalent Fab fragment of chimeric monoclonal antibody cG250 directed against carbonic anhydrase IX. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2010. 2010.
88. Chopra A. [111In]-Labeled monovalent Fab fragment of chimeric monoclonal antibody cG250 directed against carbonic anhydrase IX. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2010.2010.
89. Chopra A. [111In]-Labeled chimeric monoclonal antibody cG250 directed against carbonic anhydrase IX. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2010. 2010.
90. Stillebroer, A.B.; Oosterwijk, E.; Oyen, W.J.; Mulders, P.F.; Boerman, O.C. Radiolabeled antibodies in renal cell carcinoma. Cancer Imaging, 2007, 7, 179-188.
91. Zat'ovicová, M.; Tarábková, K.; Svastová, E.; Gibadulinová, A.; Mucha, V.; Jakubícková, L.; Biesová, Z.; Rafajová, M.; Ortova Gut, M.; Parkkila, S.; Parkkila, A.K.; Waheed, A.; Sly, W.S.; Horak, I.; Pastorek, J.; Pastoreková, S. Monoclonal antibodies generated in carbonic anhydrase IX-deficient mice recognize different domains of tumour-Associated hypoxia-induced carbonic anhydrase IX. J. Immunol. Methods, 2003, 282, 117-134. (Pubitemid 37357038)
92. Ahlskog, J.K.; Schliemann, C.; Mårlind, J.; Qureshi, U.; Ammar, A.; Pedley, R.B.; Neri, D. Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br. J. Cancer, 2009, 101, 645-657.
93. Xu, C.; Lo, A.; Yammanuru, A.; Tallarico, A.S.; Brady, K.; Murakami, A.; Barteneva, N.; Zhu, Q.; Marasco, W.A. Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS One, 2010, 5, e9625.
94. Murri-Plesko, M.T.; Hulikova, A.; Oosterwijk, E.; Scott, A.M.; Zortea, A.; Harris, A.L.; Ritter, G.; Old, L.; Bauer, S.; Swietach, P.; Renner, C. Antibody inhibiting enzymatic activity of tumour-Associated carbonic anhydrase isoform IX. Eur. J. Pharmacol., 2011, 657, 173-183.
95. Supuran, C.T. Carbonic anhydrases as drug targets. Curr. Pharm. Des., 2008, 14, 601-602.
96. Scozzafava, A.; Mastrolorenzo, A.; Supuran, C.T. Modulation of carbonic anhydrase activity and its applications in therapy. Expert Opin. Ther. Pat., 2004, 14, 667-702. (Pubitemid 38702328)
97. Pastorekova, S.; Parkkila, S.; Pastorek, J.; Supuran, C.T. Carbonic anhydrases: Current state of the art, therapeutic applications and future prospects. J. Enz. Inhib. Med. Chem., 2004, 19, 199-229. (Pubitemid 39004275)
98. Supuran, C. T. Carbonic anhydrase inhibitors. Bioorg. Med. Chem. Lett., 2010, 20, 3467-3474.
99. Supuran, C. T.; Scozzafava, A.; Casini, A. Carbonic anhydrase inhibitors. Med. Res. Rev., 2003, 23, 146-189. (Pubitemid 36241096)
100. Pastorekova, S.; Casini, A.; Scozzafava, A.; Vullo, D.; Pastorek, J.; Supuran, C.T. Carbonic anhydrase inhibitors: The first selective, membraneimpermeant inhibitors targeting the tumor-Associated isozyme IX. Bioorg. Med. Chem. Lett., 2004, 14, 869-873. (Pubitemid 38167605)
101. Thiry, A.; Dogné, J.-M.; Masereel, B.; Supuran C.T. Targeting tumorassociated carbonic anhydrase IX in cancer therapy. Trends Pharmacol. Sci., 2006, 27, 566-573. (Pubitemid 44574507)
102. Ahlskog, J.K.J.; Dumelin, C.E.; Trüssel, S.; Marlind, J.; Neri, D. In vivo targeting of tumor-Associated carbonic anhydrases using acetazolamide derivatives. Bioorg. Med. Chem. Lett., 2009, 19, 4851-4856.
103. Dubois, L.; Lieuwes, N.G.; Maresca, A.; Thiry, A.; Supuran, C.T.; Scozzafava, A.; Wouters, B.G.; Lambin, P. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. Radiother. Oncol., 2009, 92, 423-428.
104. Dubois, L.; Peeters, S.; Lieuwes, N.G.; Geusens, N.; Thiry, A.; Wigfield, S.; Carta, F.; McIntyre, A.; Scozzafava, A.; Dogné, J.M.; Supuran, C.T.; Harris, A.L.; Masereel, B.; Lambin, P. Radiother. Oncol., 2011, in press.
105. Pacchiano, F.; Carta, F.; McDonald, P.C.; Lou, Y.; Vullo, D.; Scozzafava, A.; Dedhar, S.; Supuran, C.T. Ureido-substituted benzenesulfonamides potently inhibit carbonic anhydrase IX and show antimetastatic activity in a model of breast cancer metastasis. J. Med. Chem., 2011, 54, 1896-902.
106. Maresca, A.; Temperini, C.; Vu, H.; Pham, N.B.; Poulsen, S.A.; Scozzafava, A.; Quinn, R.J.; Supuran, C.T. Non-zinc mediated inhibition of carbonic anhydrases: Coumarins are a new class of suicide inhibitors. J. Am. Chem. Soc., 2009, 131, 3057-3062.
107. Maresca, A.; Temperini, C.; Pochet, L.; Masereel, B.; Scozzafava, A.; Supuran, C.T. Deciphering the mechanism of carbonic anhydrase inhibition with coumarins and thiocoumarins. J. Med Chem., 2010, 53, 335-344.
108. Maresca, A.; Supuran, C.T. Coumarins incorporating hydroxy-And chloromoieties selectively inhibit the transmembrane, tumor-Associated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II. Bioorg Med. Chem. Lett., 2010, 20, 4511-4514.
109. Lou, Y.; McDonald, P.C.; Oloumi, A.; Chia, S.K.; Ostlund, C.; Ahmadi, A.; Kyle, A.; Auf dem Keller, U.; Leung, S.; Huntsman, D.G.; Clarke, B.; Sutherland, B.W.; Waterhouse, D.; Bally, M.B.; Roskelley, C.D.; Overall, C.M.; Minchinton, A.; Pacchiano, F.; Carta, F.; Scozzafava, A.; Touisni, N.; Winum, J.Y.; Supuran, C.T.; Dedhar, S. Targeting Tumor Hypoxia: Suppression of Breast Tumor Growth and Metastasis by Novel Carbonic Anhydrase IX Inhibitors. Cancer Res., 2011, 71, 3364-3376.
110. Maresca, A.; Scozzafava, A.; Supuran, C.T. 7,8-Disubstituted-but not 6,7-disubstituted coumarins selectively inhibit the transmembrane, tumorassociated carbonic anhydrase isoforms IX and XII over the cytosolic ones I and II in the low nanomolar/subnanomolar range. Bioorg. Med. Chem. Lett., 2010, 20, 7255-7258.
111. Parkkila, S.; Innocenti, A.; Kallio, H.; Hilvo, M.; Scozzafava, A.; Supuran, C.T. The protein tyrosine kinase inhibitors imatinib and nilotinib strongly inhibit several mammalian β-carbonic anhydrase isoforms. Bioorg. Med. Chem. Lett., 2009, 19, 4102-4106.
112. Li, S.; Kussie, P.; Ferguson, K.M. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure, 2008, 16, 216-227. (Pubitemid 351215209)
113. Freeman, M.M.; Seaman, M.S.; Rits-Volloch, S.; Hong, X.; Kao, C.Y.; Ho, D.D.; Chen, B. Crystal structure of HIV-1 primary receptor CD4 in complex with a potent antiviral antibody. Structure, 2010, 18, 1632-1641.